Mostrar el registro sencillo del ítem
Effectiveness and safety of dalbavancin in France: a prospective, multicentre cohort study
| dc.rights.license | open | en_US |
| hal.structure.identifier | Centre Hospitalier Universitaire de Nice [CHU Nice] | |
| dc.contributor.author | COURJON, Johan | |
| hal.structure.identifier | Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS] | |
| dc.contributor.author | SENNEVILLE, Eric | |
| hal.structure.identifier | CHU Mont de Marsan | |
| dc.contributor.author | ILLES, Hajnal-Gabriela | |
| hal.structure.identifier | Centre Hospitalier Universitaire [CHU Grenoble] [CHUGA] | |
| dc.contributor.author | PAVESE, Patricia | |
| hal.structure.identifier | Centre d'investigation clinique (CIC) de Nantes -CIC Plurithématique [CIC 0004 - Nantes] | |
| dc.contributor.author | BOUTOILLE, David | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | DAOUD-PINEAU, Frederic | |
| dc.contributor.author | DUNKEL, Nathalie | |
| hal.structure.identifier | ARN régulateurs bactériens et médecine [BRM] | |
| hal.structure.identifier | Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] | |
| dc.contributor.author | TATTEVIN, Pierre | |
| dc.date.accessioned | 2024-10-30T12:42:20Z | |
| dc.date.available | 2024-10-30T12:42:20Z | |
| dc.date.issued | 2023-08-04 | |
| dc.identifier.issn | 0924-8579 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/202992 | |
| dc.description.abstractEn | OBJECTIVES: Dalbavancin is a lipoglycopeptide antibiotic approved for the treatment of acute bacterial skin and skin structure infections. However, several studies have suggested that it is used mostly for off-label indications. We aimed to describe the use of dalbavancin in patients who received at least one dose of the antibiotic in France. METHODS: Prospective, observational, multicentre study conducted in France from September 2018 to April 2020. The primary outcome was the clinical response at 30 days after the last dalbavancin dose. RESULTS: A total of 151 patients in 16 centres were included in this study. The main infection sites were bone and joint infections (55.0%), multisite infections (15.9%), and vascular infections (14.6%), and the primary pathogens were coagulase-negative staphylococci (N = 82), Staphylococcus aureus (N = 51), and enterococci (N = 27). Most patients (71.5%) received three previous antibiotic treatments. The number of dalbavancin injections per patient was 1 in 26 patients (17.2%), 2 in 95 patients (62.9%), 3 in 17 patients (11.3%), and more than 3 in 13 patients (8.6%), with a mean cumulative dose of 3089 ± 1461 mg per patient. Among the 129 patients with a complete follow-up, clinical success was achieved in 119 patients (92.2%). At least 1 adverse event was reported in 67 patients (44.4%), including 12 (7.9%) patients with dalbavancin-related adverse events. CONCLUSIONS: The results of the study showed that dalbavancin is used mostly for off-label indications and in heavily pretreated patients in France. The clinical response at 30 days after the last dose was favourable in most patients, with a good safety profile. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Antibiotics | |
| dc.subject.en | Dalbavancin | |
| dc.subject.en | Effectiveness | |
| dc.subject.en | Off-label | |
| dc.subject.en | Safety | |
| dc.title.en | Effectiveness and safety of dalbavancin in France: a prospective, multicentre cohort study | |
| dc.title.alternative | Int J Antimicrob Agents | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.ijantimicag.2023.106945 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Microbiologie et Parasitologie | en_US |
| bordeaux.journal | International Journal of Antimicrobial Agents | en_US |
| bordeaux.page | 106945 | en_US |
| bordeaux.volume | 62 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 4 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | AHEAD_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.import.source | hal | |
| hal.identifier | hal-04196650 | |
| hal.version | 1 | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | false | |
| workflow.import.source | hal | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=International%20Journal%20of%20Antimicrobial%20Agents&rft.date=2023-08-04&rft.volume=62&rft.issue=4&rft.spage=106945&rft.epage=106945&rft.eissn=0924-8579&rft.issn=0924-8579&rft.au=COURJON,%20Johan&SENNEVILLE,%20Eric&ILLES,%20Hajnal-Gabriela&PAVESE,%20Patricia&BOUTOILLE,%20David&rft.genre=article |
